FINWIRES · TerminalLIVE
FINWIRES

Correction: Wall Street Logs Back-to-Back Losses Amid US-Iran Talks Uncertainty

-- (Corrects the day to Tuesday in first para)

Equities on Wall Street fell for a second straight session on Tuesday amid doubts over a fresh round of negotiations between the US and Tehran.

The three main US stock indexes lost 0.6% each, with the S&P 500 closing at 7,064. The Nasdaq Composite ended at 24,260, while the Dow Jones Industrial Average settled at 49,149.4. Barring energy, all sectors were in the red, led by real estate.

Shortly after market close, US President Donald Trump announced the extension of a two-week ceasefire deal with Iran, though he said the naval blockade of Iranian ports will continue. The truce was announced on April 7.

Pakistan Prime Minister Shehbaz Sharif and Field Marshal Asim Munir asked for an extension, Trump said in a Truth Social post.

The blockade of the crucial Strait of Hormuz had fueled uncertainty around a second round of discussions between Washington and Iran, likely to be held in Pakistan, CNN reported Tuesday. US Vice President JD Vance's plans to depart for Islamabad had reportedly been put on hold amid Iran's reluctance to participate in peace talks.

West Texas Intermediate crude oil was last up 1.7% at $88.90 per barrel, while Brent climbed 3.5% to $98.82.

US Treasury yields were higher, with the 10-year rate up 4.5 basis points at 4.30% and the two-year rate rising 6.5 basis points to 3.79%.

Meanwhile, Kevin Warsh said the Federal Reserve, under his leadership, would be independent from the White House, CNBC reported. He made the remarks at his Senate Banking Committee confirmation hearing. Warsh is Trump's Fed chair nominee.

In economic news, US retail sales last month logged the largest rise since March 2025 amid a surge in spending at gasoline stations as the Middle East conflict boosted energy prices, official data showed.

"We expected that the headline (figure) would be gaudy due to the increase in gas prices and a pickup in unit auto sales, but the strength in other categories was surprising," Jefferies said in a note. "There is no evidence here that higher gasoline prices have motivated the consumer to tighten the belt elsewhere just yet."

US pending home sales increased more than expected in March despite higher mortgage rates, data from the National Association of Realtors showed.

In company news, Apple (AAPL) shares fell 2.5%, among the worst performers on the Dow. The iPhone maker said late Monday that Tim Cook will step down as chief executive and become executive chairman, with hardware engineering veteran John Ternus set to succeed him as CEO.

Tractor Supply (TSCO) shares tumbled nearly 12%, the steepest decline on the S&P 500. The retailer logged first-quarter results that missed Wall Street's projections amid a below-average performance of its companion animal product business.

UnitedHealth Group (UNH) raised its full-year earnings outlook, as the health insurance giant recorded an unexpected annual increase in its first-quarter results. The company's shares jumped 7%, the biggest gainer on the Dow and among the best performers on the S&P 500.

D.R. Horton's (DHI) fiscal second-quarter results came in better than expected, though the homebuilder tempered its full-year revenue outlook. The company's shares advanced 5.8%, among the biggest gains on the S&P 500.

Gold was down 2.1% at $4,726.10 per troy ounce, while silver dropped 4.4% to $76.53 per ounce.

Related Articles

Asia

Corporate Travel Management Expects to Reverse Up to 118 Million Pounds Sterling of Revenue From Prior Results

Corporate Travel Management (ASX:CTD) now expects to reverse up to 118 million pounds sterling of revenue from fiscal year 2025 and prior years' results, up from a previously flagged amount of 77.6 million pounds sterling, according to a Wednesday filing with the Australian bourse.The development comes after the company hired KPMG to perform a forensic accounting review for certain years, with KPMG identifying areas of concern regarding the recognition of the UK group's concluded customer contracts and other revenue.The company said revenue of up to about 10 million pounds sterling may need to be reversed in the fiscal first-half results, depending on the outcome of commercial discussions with certain customers. The review confirmed that certain customers were charged above the contractual entitlement.Corporate Travel Management has made "significant changes" within its UK business, especially across financial controls and operational processes, it said, adding that the review has not identified any issues in other regions.The company aims to release audited fiscal year 2025 and reviewed fiscal first-half 2026 financial statements in the second quarter of the year.

$ASX:CTD
Asia

Northern Star Resources' Gold Sales Fall in March Quarter

Northern Star Resources (ASX:NST) said that the total gold sold for the March quarter was 380,807 ounces at an all-in sustaining cost (AISC) of AU$2,709 per ounce, according to a Wednesday Australian bourse filing.Total gold sold was 385,441 ounces at an AISC of AU$2,246 per ounce in the March 2025 quarter, an earlier filing showed.The company expects gold sales in fiscal 2026 to exceed 1.5 million ounces, with AISC projected between AU$2,600 and AU$2,800 per ounce.The company reported net cash of AU$320 million after paying a AU$347 million cash dividend, with total cash and bullion holdings amounting to AU$1.18 billion as of March 31.Northern Star Resources' shares shed around 2% in recent Wednesday trade.

$ASX:NST
Asia

Eisai, Merck's Phase 3 Kidney Cancer Drug Combo Trial Fails to Meet Survival Endpoints

Japanese pharmaceutical firm Eisai (TYO:4523) and U.S.-based Merck's experimental combination therapies failed to meet the dual primary endpoints of progression-free survival and overall survival in a Phase 3 trial.The trial was evaluating first-line treatment for advanced clear cell renal cell carcinoma, a form of kidney cancer that accounts for approximately 80% of all cases, according to a joint statement on Tuesday.The LITESPARK-012 study tested two regimens: Keytruda plus Lenvima plus Welireg, and MK-1308A (a co-formulation of Keytruda with an investigational antibody) plus Lenvima, against the established combination of Keytruda and Lenvima in 1,688 patients.An interim analysis revealed that neither experimental combination met the study's two primary goals of improving overall survival and progression-free survival compared with the standard treatment.

$TYO:4523